Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (161-170 of 466) with videos related to

Pageof 47
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Haematologica|May 11, 2019
Cryptic insertion of <i>MYC</i> exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of "<i>MYC</i>-negative" Burkitt lymphomaRabea Wagener, Susanne Bens, Umut H Toprak, et al.
Oncotarget|October 23, 2018
Functional characterization of phospholipase C-γ<sub>2</sub> mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorderClaudia Walliser, Martin Wist, Elisabeth Hermkes, et al.
International Journal of Cancer|October 12, 2005
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancerStephan Wolf, Daniel Mertens, Armin Pscherer, et al.
The Journal of Biological Chemistry|March 19, 2020
Noncatalytic Bruton's tyrosine kinase activates PLCγ<sub>2</sub> variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cellsMartin Wist, Laura Meier, Orit Gutman, et al.
Blood|October 21, 2017
Analysis of <i>ITGB2</i> rare germ line variants in chronic lymphocytic leukemiaGrace Tiao, M Reina Improgo, Eugen Tausch, et al.
Haematologica|December 3, 2009
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemiaDirk Kienle, Axel Benner, Carolin Läufle, et al.
Blood|December 1, 2010
DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testingJulia Mohr, Hanne Helfrich, Maxi Fuge, et al.
Leukemia & Lymphoma|September 9, 2022
Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemiaPaurnima Patil, Umut H Toprak, Julian Seufert, et al.
Blood Advances|March 18, 2025
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemiaValentin Goede, Kirsten Fischer, Sandra Robrecht, et al.
Pageof 47

Showing results (161-170 of 466) with videos related to

Sort By:
Pageof 47
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Haematologica|May 11, 2019
Cryptic insertion of <i>MYC</i> exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of "<i>MYC</i>-negative" Burkitt lymphomaRabea Wagener, Susanne Bens, Umut H Toprak, et al.
Oncotarget|October 23, 2018
Functional characterization of phospholipase C-γ<sub>2</sub> mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorderClaudia Walliser, Martin Wist, Elisabeth Hermkes, et al.
International Journal of Cancer|October 12, 2005
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancerStephan Wolf, Daniel Mertens, Armin Pscherer, et al.
The Journal of Biological Chemistry|March 19, 2020
Noncatalytic Bruton's tyrosine kinase activates PLCγ<sub>2</sub> variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cellsMartin Wist, Laura Meier, Orit Gutman, et al.
Blood|October 21, 2017
Analysis of <i>ITGB2</i> rare germ line variants in chronic lymphocytic leukemiaGrace Tiao, M Reina Improgo, Eugen Tausch, et al.
Haematologica|December 3, 2009
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemiaDirk Kienle, Axel Benner, Carolin Läufle, et al.
Blood|December 1, 2010
DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testingJulia Mohr, Hanne Helfrich, Maxi Fuge, et al.
Leukemia & Lymphoma|September 9, 2022
Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemiaPaurnima Patil, Umut H Toprak, Julian Seufert, et al.
Blood Advances|March 18, 2025
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemiaValentin Goede, Kirsten Fischer, Sandra Robrecht, et al.
Pageof 47